PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)

被引：0
|
作者：
Machiels, J. P. [1 ]
Kaminsky, M. C. [2 ]
Keller, U. [3 ]
Bruemmendorf, T. H. [4 ]
Goddemeier, T. [5 ]
Forssman, U. [6 ]
Delord, J. P. [7 ]
机构：
[1] Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Ctr Alexis Vautrin, Dept Med Oncol, Nancy, France
[3] Tech Univ Munich, Med Klin 3, Munich, Germany
[4] Univ Klinikum Aachen, Aachen, Germany
[5] Merck KGaA, Global Clin Operat Global Biostat, Darmstadt, Germany
[6] Merck Serono SA, Global Clin Dev Unit Oncol, Geneva, Switzerland
[7] Ctr Claudius Regaud, Clin Resarch Unit, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [1] Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Humblet, Y
    Vega-Villegas, E
    Mesia, R
    Awada, A
    Geoffrois, L
    Borel, C
    Hitt, R
    Amellal, N
    Bessa, EH
    Bourhis, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 491S - 491S
  • [2] Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
    Jean-Pascal Machiels
    Marie-Christine Kaminsky
    Ulrich Keller
    Tim H. Brümmendorf
    Thomas Goddemeier
    Ulf Forssmann
    Jean-Pierre Delord
    Investigational New Drugs, 2013, 31 : 1207 - 1216
  • [3] Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
    Machiels, Jean-Pascal
    Kaminsky, Marie-Christine
    Keller, Ulrich
    Bruemmendorf, Tim H.
    Goddemeier, Thomas
    Forssmann, Ulf
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1207 - 1216
  • [4] Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).
    Vermorken, J. B.
    Mesia, R.
    Vega-Villegas, M. E.
    Remenar, E.
    Hitt, R.
    Kawecki, A.
    Rottey, S.
    Zabolotnyy, D.
    Erfan, J.
    Amellal, N.
    Antwerpen, U. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 289S - 289S
  • [5] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial
    Gauler, T. C.
    Clement, P. M.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Brummendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Vermorken, J. B.
    ONKOLOGIE, 2012, 35 : 193 - 194
  • [6] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial
    Vermorken, Jan Baptist
    Peyrade, Frederic
    Krauss, Juergen
    Mesia, Ricard
    Remenar, Eva
    Gauler, Thomas C.
    Keilholz, Ulrich
    Delord, Jean-Pierre
    Schafhausen, Philippe
    Erfan, Jozsef
    Brummendorf, Tim H.
    Iglesias, Lara
    Bethe, Ullrich
    de La Bourdonnaye, Guillaume
    Clement, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
    Knoedler, Maren
    Dietz, Andreas
    Gauler, Thomas Christoph
    Gruenwald, Viktor
    Stoehlmacher, Jan
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Schroeder, Michael
    Maschmeyer, Georg
    Rethwisch, Volker
    Haxel, Boris
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] SAFETY AND EFFICACY OF CISPLATIN PLUS 5-FU AND CETUXIMAB IN HPV-POSITIVE AND HPV-NEGATIVE RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN): ANALYSIS OF THE PHASE III EXTREME TRIAL
    Psyrri, A.
    Licitra, L.
    De Blas, B.
    Celik, I.
    Vermorken, J. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 334 - 335
  • [10] Cisplatin/5-FU 100/1000 in Japanese Patients With Recurrent/Metastatic SCCHN Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Tahara, M.
    Onozawa, Y.
    Fujii, H.
    Monden, N.
    Yana, I.
    Otani, S.
    Hasegawa, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 509 - 510
12345